目的：研究中药通补三升汤对晚期肺鳞癌化疗患者毒副反应及肿瘤无进展生存期（Progression-free survival，PFS）的干预作用。方法：选取符合标准的83例晚期肺鳞癌患者，按患者意愿分为治疗组42例及对照组41例，对照组采用GP方案（吉西他滨+顺铂）化疗，治疗组接受化疗的同时服用中药通补三升汤。评价两组患者化疗期间毒副反应及近期疗效，记录患者PFS。结果：两组患者治疗后粒细胞水平降低无差异（P=0.115），两组患者的近期疗效亦无差异（P=0.081）；治疗组发生恶心呕吐及血小板水平降低的几率低于对照组（P=0.037、P=0.040），治疗组患者的PFS较对照组患者延长（4.31±0.24 VS 3.78±0.16月，P=0.043）。结论：中药通补三升汤不能改善肺鳞癌患者化疗期间的粒细胞水平降低程度，也不能提高近期有效率（Response Rate RR），但能延长PFS，并对化疗期间的恶心呕吐反应及血小板水平降低有改善作用。

This study was aimed to investigate the efficacy of Tong-Bu San-Sheng (TBSS) Decoction to reduce the toxicity and side effects of chemotherapy, as well as prolong progression-free survival (PFS) for advanced lung squamous carcinoma patients who received chemotherapy. A total of 83 lung squamous carcinoma cases were divided into two groups by patients’ wishes. The control group contained 41 cases were treated by the chemotherapy of gemcitabine plus cisplatin (GP). The trial group contained 42 cases were treated by chemotherapy plus Chinese herbal medicine TBSS decoction. The toxicity and side effects of chemotherapy, as well as short-term outcome were evaluated. PFS of patient was recorded. The results showed that there were no differences on granulocytopenia (P = 0.115) or short-term outcome (P = 0.081) for patients of both groups after chemotherapy. The percentages of nausea, vomiting and thrombocytopenia in the trial group were lower than that in the control group (P = 0.037, P = 0.040). The PFS of patients in the trail group were prolonged compared to patients in the control group (4.31 ± 0.24 VS 3.78 ± 0.16 month; P = 0.043). It was concluded that Chinese herbal medicine TBSS decoction cannot reduce granulocytopenia caused by chemotherapy, or improve the tumor response rate (RR) of short-term outcome. However, it can prolong PFS, relieve nausea, vomiting and thrombocytopenia during chemotherapy.

广西中医药管理局广西中医药民族医药科研项目（GZZC14-76）：通补三升汤对肺鳞癌化疗患者生存期影响的临床研究，负责人：王志光。